In a groundbreaking move for the life sciences industry, Clasp Therapeutics and Capstan Therapeutics unveiled separate funding initiatives totaling an impressive $325 million. These funds promise to propel their innovative treatments for various health conditions, including cancer and autoimmune diseases, to new heights.
Clasp Therapeutics: Revolutionizing Cancer Treatment
Clasp Therapeutics, with bases in Cambridge, Massachusetts, and Rockville, Maryland, spearheads the development of cutting-edge immuno-oncology therapies. Their focus lies in pioneering next-generation T cell engagers (TCEs), meticulously tailored to each patient’s immune system. These therapies exhibit unprecedented precision in targeting a wide array of challenging tumor types.
Led by a consortium including Catalio Capital Management, Third Rock Ventures, and Novo Holdings, Clasp secured a monumental $150 million in financing. Notable contributors also include Vivo Capital, Cure Ventures, and Alexandria Venture Investments, among others.
